Durvalumab plus chemoradiation for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer (cancer only in one lung and nearby lymph nodes, not spread to other parts of the body).
- You have not had immunotherapy before (like drugs that help your immune system fight cancer).
- You have not had radiation to your chest in the past.
- Your overall health is good enough to perform daily activities (ECOG 0 or 1) and you weigh more than 40 kg (about 88 lbs).
- Your heart, lungs, liver, kidneys, and blood counts are working well, as shown by recent tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This trial tests whether the immunotherapy drug durvalumab can help keep limited-stage small cell lung cancer from coming back after standard treatment. You would receive durvalumab as a 'consolidation' (maintenance) therapy.
This phase 2 trial studies whether durvalumab given with consolidation radiotherapy can help people with extensive-stage small cell lung cancer that has only a few metastases. It builds on initial chemotherapy and immunotherapy response, then targets the chest and limited metastatic spots with radiation.
This trial tests whether adding immunotherapy (durvalumab) to standard chemotherapy after surgery can help prevent small cell lung cancer from coming back. It is for people who have had their cancer completely removed and are well enough to start treatment soon after surgery.
Hear when a new SCLC, Limited Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.